10-Q: Quince Therapeutics Faces Going Concern Doubt Amid Rising R&D Costs

Quince Therapeutics reported increased net losses and R&D expenses for Q3 2025, raising substantial doubt about its ability to continue as a going concern despite clinical trial progress and recent financing.

Summary

• Net loss for the three months ended September 30, 2025, increased to $13.4 million from $5.5 million in the prior year.
• Net loss for the nine months ended September 30, 2025, was $44.5 million, comparable to $44.4 million in the prior year.
• Research and development expenses rose significantly by 64% to $8.1 million for Q3 2025 and 78% to $22.8 million for the nine months, driven by the Phase 3 NEAT clinical trial.
• Cash, cash equivalents, and short-term investments totaled $26.3 million as of September 30, 2025.
• Management concluded that substantial doubt exists regarding the ability to continue as a going concern for the next 12 months due to insufficient funding.
• Enrollment for the Phase 3 NEAT clinical trial for eDSP in Ataxia-Telangiectasia (A-T) patients was completed on July 16, 2025, with topline results expected in Q1 2026.
• Secured $11.5 million in gross proceeds from a June 2025 private placement and raised an additional $4.3 million through its ATM program during the nine months ended September 30, 2025.
• The ATM program was expanded to $75.0 million in October 2025, with $68.5 million remaining available.
• The EIB Loan's minimum cash covenant was further amended in September 2025, reducing the required balance to 5.0 million euros for Q1 2026.

Sentiment

Score: 3

Explanation: While there is positive clinical progress (Phase 3 enrollment complete, iDSMB recommendation, pipeline expansion), the severe liquidity issues and explicit 'going concern' warning, coupled with increasing net losses and cash burn, indicate a highly precarious financial position. The need for immediate and substantial capital raises overshadows the clinical advancements.

Positives

• Completed enrollment of the Phase 3 NEAT clinical trial for eDSP in A-T patients on July 16, 2025, with 105 participants.
• The independent Data and Safety Monitoring Board (iDSMB) recommended continuing the Phase 3 NEAT study without modifications.
• 100% of NEAT study participants elected to transition to the Open-Label Extension (OLE) study, indicating patient and physician interest.
• FDA Fast Track designation and Special Protocol Assessment (SPA) agreement for the eDSP System for A-T.
• Strategic partnership with Option Care Health, Inc. established for commercial development and launch of eDSP in the U.S.
• Qualitative payer research showed broad support for eDSP as a potential first-to-market treatment for A-T, assuming positive study results.
• Expanded development pipeline to include Duchenne muscular dystrophy (DMD) as a second indication for eDSP, with a Phase 2 study planned for 2026.
• Successfully raised $11.5 million gross proceeds from a private placement in June 2025 and $4.3 million from ATM offerings during the nine months ended September 30, 2025.
• The ATM program was significantly increased to $75.0 million in October 2025, providing additional funding capacity.
• EIB Loan covenants were amended to reduce the minimum cash balance requirement for Q1 2026, providing some financial flexibility.

Negatives

• Net loss for the three months ended September 30, 2025, increased by 145% to $13.4 million compared to $5.5 million in the prior year.
• Accumulated deficit reached $421.0 million as of September 30, 2025.
• Cash, cash equivalents, and short-term investments of $26.3 million as of September 30, 2025, are insufficient to fund operations for the next 12 months.
• Management concluded that substantial doubt exists about the ability to continue as a going concern.
• Net cash used in operating activities increased by $6.6 million to $30.9 million for the nine months ended September 30, 2025, compared to $24.3 million in the prior year.
• Interest income decreased by $0.4 million for Q3 2025 and $1.4 million for the nine months ended September 30, 2025, due to decreased yields and average balances.
• A non-cash goodwill impairment charge of $17.1 million was recorded during the nine months ended September 30, 2024, indicating a significant reduction in the fair value of acquired assets.
• Fair value adjustment for warrants resulted in a $4.2 million charge for the nine months ended September 30, 2025, primarily due to changes in common stock price.
• The EIB Loan of $11.7 million (10.0 million euros) is classified as a current portion of debt, indicating a near-term repayment obligation.

Risks

• Uncertainty of results of clinical trials and reaching milestones.
• Uncertainty of regulatory approval of potential drug candidates.
• Uncertainty of market acceptance of drug candidates.
• Competition from substitute products and larger companies.
• Challenges in securing and protecting proprietary technology.
• Dependence on strategic relationships and key individuals.
• Reliance on sole source suppliers.
• Inability to obtain additional funding on acceptable terms, if at all, which could lead to delays or termination of development efforts.
• Future sales of common stock in the public market could cause the share price to fall due to dilution.
• Outstanding warrants include put rights upon a fundamental transaction, potentially requiring cash repurchase at Black-Scholes value, which could hinder beneficial transactions or increase their cost.
• Potential recoupment of up to $2.7 million in Australian R&D tax incentives if tax authorities determine expenditures were not at risk.

Future Outlook

The company expects to report topline results from the Phase 3 NEAT clinical trial in the first quarter of 2026 and plans to submit a New Drug Application (NDA) to the U.S. FDA in the second half of 2026, assuming positive study results. It also plans to initiate a Phase 2 clinical study for eDSP in Duchenne muscular dystrophy (DMD) in 2026. The company anticipates needing additional funding to support operations beyond the second quarter of 2026 (or second half of 2026 if warrants are fully exercised) and intends to pursue various financing options.

Management Comments

• "Our strategic focus is to apply our resources and capital toward the advancement of our proprietary AIDE technology platform and Phase 3 lead asset, eDSP, targeted to treat A-T."
• "We believe that the findings of such research [qualitative payer research] were highly encouraging with payers recognizing the significant unmet need in A-T and expressing broad support for eDSP as a potential first-to-market treatment, assuming positive NEAT study results."
• "We consider DMD an excellent indication for eDSP as corticosteroids are the standard of care for this rare disease, and their utility is limited by significant toxicities."
• "Based on our current operating plan, we believe that our cash and cash equivalents balance as of September 30, 2025 will not be sufficient to fund operations and capital expenditures for the twelve months following the filing of this Quarterly Report on Form 10-Q, and we will need to obtain additional funding."
• "Because of the uncertainty in securing additional funding and the insufficient amount of cash and cash equivalent resources as of September 30, 2025, we concluded that substantial doubt exists with respect to our ability to continue as a going concern within one year after the date that these unaudited condensed consolidated financial statements are issued."

Industry Context

Quince Therapeutics operates in the highly specialized and capital-intensive rare disease biotechnology sector, focusing on innovative drug delivery platforms like AIDE. The company's lead asset, eDSP for Ataxia-Telangiectasia (A-T), addresses a significant unmet medical need with no approved treatments, positioning it for a potential first-to-market advantage if successful. The expansion into Duchenne muscular dystrophy (DMD) aligns with a strategy to leverage its platform for conditions where chronic corticosteroid use is standard but limited by toxicity, a common challenge in rare disease management. The reliance on external financing and strategic partnerships is typical for clinical-stage biotech companies, especially those with a going concern warning.

Comparison to Industry Standards

• The filing does not provide specific comparisons to comparable companies, projects, or results within the industry. It highlights the significant unmet medical need in A-T and the potential for eDSP as a first-to-market treatment, but without specific benchmarks or competitor data.

Corporate Governance

Stakeholder Impact

• Shareholders: Significant dilution risk from ongoing and future equity raises (ATM program, private placements, warrant exercises). Potential for stock price volatility due to going concern warning and need for capital.
• Employees: Continued employment dependent on successful capital raises and clinical trial outcomes. Stock-based compensation value tied to share price performance.
• Creditors (EIB): Debt covenants have been amended to provide flexibility, but the loan is classified as current, indicating near-term repayment obligations. Additional remuneration tied to future revenue.
• Patients (A-T, DMD): Potential for a new treatment (eDSP) if clinical trials are successful and regulatory approval is obtained. Delays in funding could impact development.
• Partners (Option Care Health): Commercial success of eDSP is contingent on regulatory approval and market adoption.

Next Steps

• Report topline results from the Phase 3 NEAT clinical trial in Q1 2026.
• Submit a New Drug Application (NDA) to the U.S. FDA in H2 2026, assuming positive NEAT study results.
• Initiate a Phase 2 clinical study for eDSP in Duchenne muscular dystrophy (DMD) in 2026.
• Continue study initiation activities for the European Union pediatric investigational plan (PeD) study for eDSP in smaller A-T patients.
• Seek additional funding through public offerings, private financing, strategic partnerships, licensing, or collaborations to address the going concern issue.
• Continue commercial readiness activities for eDSP.
• Make quarterly 2% cash interest payments on EIB Loan Tranches A and B during fiscal year 2025.
• Pay 1% fixed interest rate on EIB Loan Tranches A and B on March 31, 2026.
• Begin additional remuneration payments to EIB from January 1, 2026, through December 31, 2032, based on revenue.

Key Dates

Recommendation

Substantial doubt exists about the ability to continue as a going concern, explicitly stated by management, due to insufficient cash to fund operations for the next 12 months. Increasing net losses, high cash burn from R&D, and the continuous need for capital raises create significant financial instability and dilution risk. The classification of the EIB loan as current debt further exacerbates liquidity concerns. Despite promising clinical assets, the severe financial distress and ongoing need for dilutive financing make the stock a high-risk investment with a strong likelihood of further value erosion.

Keywords

Quince Therapeutics, QNCX, 10-Q, Biotechnology, Rare Diseases, AIDE Technology, eDSP, Ataxia-Telangiectasia, A-T, Phase 3 Clinical Trial, NEAT Study, Duchenne Muscular Dystrophy, DMD, Going Concern, SEC Filing, Financial Results, Clinical Development, Drug Delivery, Red Blood Cells, EIB Loan, Capital Raise, Warrants, Nasdaq